Geron Corporation (GERN) obtained FDA approval for pipeline candidate imetelstat for the treatment of adult patients with low to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks. The agency approved the drug for patients who either did not respond or lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). Shares of the company rose 18% on Jun 7, on the news. The FDA approved imetelstat, ...